The screened hub genes, including IL6, ITGA1, PTK2, ITGB3, ITGB5, CCL2, IL15, VCAM1, GZMB, APOE, ITGB8, LAMA4, LAMC2, COL6A3, and TNFRSF9, were validated using the GEO dataset and single-cell sequencing data, and may be therapeutic targets in patients with COVID-19 myocarditis to prevent myocarditis progression and adverse cardiovascular events. This evidence concerns the gene CCL2 and COVID-19.